Adalimumab long-term safety/efficacy results for pediatric patients with chronic plaque psoriasis from a phase 3, randomized study - 21/04/16
Kim Papp, K. Papp Clinical Research and Probity Medical Research, University of Western Ontario, Waterloo, Ontario, Canada; Danielle Marcoux, CHU Sainte-Justine Montreal, Montreal, Quebec, Canada; Ian Landells, Nexus Clinical Research and Memorial University of Newfoundland, St. John’s, Newfoundland, Canada; Lisa Weibel, University Children’s Hospital, Zürich, Switzerland; Pierre-Dominique Ghislain, UCL St. Luc, Brussel, Belgium; Kristina Unnebrink, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany; David Williams, AbbVie Inc, North Chicago, IL, United States
Le texte complet de cet article est disponible en PDF. AbbVie Inc participated in the study design; study research; collection, analysis and interpretation of data; and writing, reviewing and approving of this publication. All authors had access to the data, and participated in the development and review. |
Vol 74 - N° 5S1
P. AB209 - mai 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?